Skip to main content
OpenTrials
Completed

NCT Number: NCT00882934

The Management of Erectile Dysfunction With Placebo Only

Placebo-controlled randomized clinical trials (RCT) are the gold standard to provide applicable evidence for clinical practice. A vast number of RCTs for treatment of several disorders has shown a mean placebo effect of 30%. Erectile dysfunction (ED) is a high prevalent disease and its first-line therapy is oral phosphodiesterase type-5 inhibitor (iPDE5) (i.e., sildenafil, vardenafil and tadalafil). Although the placebo effect in iPDE5 RCT occurred at a rate as high as 50%, in the last decade, with the revolutionary discovery of effective pharmacotherapy for ED, oral iPDE5 has become one of the most common prescribed drugs for men. The objective of this study is to evaluate the influence of patients' awareness on the composition of the therapeutic drug in the outcomes of the oral treatment for ED.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Complaint of ED for at least 6 months prior the start of the study, according to medical history and to the questionnaires IIEF, SEAR and QEQ.
  • A stable heterosexual relationship.
  • To be in good health prior the participation in the study, with no important clinical abnormalities, determined by: clinical history, physical examination, blood chemistry and hematology, urinalysis (If the standard values of the laboratory for these tests are not evidenced, subjects can be included if the researcher consider the changes as not clinically significant).

Exclusion criteria

  • History of significant cardiovascular, pulmonary, gastrointestinal, hematological, neurological (including epilepsy), locomotor, immunologic, ophthalmic, metabolic, endocrine, thromboembolic, rheumatologic, cancer, kidney or liver disease.
  • Diagnosis of psychiatric conditions, e.g. depression, anxiety, dysthymia, mania, panic, agoraphobia, social phobia, suicidal ideation, obsessive-compulsive disorder, post-traumatic stress, psychotic disorders, schizophrenia, alcoholism, dependence on psycho-active substances.
  • History of HIV, hepatitis B or hepatitis C.
  • Hyperprolactinemia or untreated hypothyroidism.
  • Any condition, which, in the opinion of the investigator, may interfere with the participation of the subject in the study (e.g. difficulty to meet the requirements of the study, attend the consultations, answer the questionnaires).
  • Report of significant clinical problems by the subject's partner, such as decreased sexual interest, pain during relations or other forms of sexual dysfunction that interfere in the relationship with the sexual partner.
  • Patient or partner willing to undergo a surgical procedure during the study period, which may interfere in the results.
  • Peyronie's disease, which may lead to impossibility to penetrate or cause pain during the sexual intercourse.
  • Use of nitrates.
  • Illiterate patient.

Treatment and study plan

Induction to efficient treatment

Other

Informative letters.

Doubt to the efficacy of treatment

Other

Informative letters.

Induction to ineffective treatment

Other

Informative letters

Primary outcomes

  1. IIEF erectile function domain score

    Time frame: 4 AND 8 Weeks

  2. Quality of Erection Questionnaire (QEQ)

    Time frame: 4 and 8 weeks

Secondary outcomes

  1. IIEF orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction domain scores

    Time frame: 4 and 8 weeks

  2. SEAR questionnaire

    Time frame: 4 and 8 weeks

  3. EDITS questionnaire

    Time frame: 4 and 8 weeks

  4. GEAQ questionnaire

    Time frame: 4 and 8 weeks

Sponsors and collaborators

Lead sponsor

Rio de Janeiro State University

Other

Registry information

Official study title

A Single-Blind, Controlled, Randomized, Parallel-Group Study of the Efficacy of Patients' Awareness on the Composition of the Experimental Drug in the Treatment of Erectile Dysfunction.

Acronym: DAFA06

Important dates

Study start
2006
Primary completion
2007
Study completion
2008
First posted
Apr 17, 2009
Registry last updated
Apr 17, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.